Skip to main content
Premium Trial:

Request an Annual Quote

Invitae Hereditary Cancer Testing Expansion

Invitae has announced an expansion of its hereditary cancer testing menu. Testing will now include blood, bone, brain, endocrine (hyperparathyroidism, thyroid cancer, and paraganglioma-pheochromocytoma), genitourinary (renal/urinary tract and prostate cancer), sarcoma, and skin cancers (melanoma and basal cell nevus syndrome). In addition, the company is introducing three new focused panels based entirely on oncology management guidelines in breast, gynecologic, and colon cancer. Invitae is also offering epidermal growth factor receptor testing for patients with strong personal and family history of lung cancer. This expanded test menu is offered at the same price and with the same flexibility as all of Invitae's genetic tests, the company said in a statement. 

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.